Quality of life with cediranib in relapsed ovarian cancer: The ICON6 phase 3 randomized clinical trial

BACKGROUND: The ICON6 trial showed that cediranib, an oral inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, improved clinical outcomes for patients with platinum‐sensitive relapsed ovarian cancer when it was used with chemotherapy and was continued as maintenance therapy. This...

Descripción completa

Detalles Bibliográficos
Autores principales: Stark, Dan P., Cook, Adrian, Brown, Julia M., Brundage, Michael D., Embleton, Andrew C., Kaplan, Richard S., Raja, Fharat A., Swart, Ann Marie W., Velikova, Galina, Qian, Wendi, Ledermann, Jonathan A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5516140/
https://www.ncbi.nlm.nih.gov/pubmed/28339098
http://dx.doi.org/10.1002/cncr.30657

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5516140/
https://www.ncbi.nlm.nih.gov/pubmed/28339098
http://dx.doi.org/10.1002/cncr.30657

Ejemplares similares